Cancer Biomarkers

Protein Biomarkers can be used as biomarkers for early detection of cancers especially used for the identification of breast cancer. Diagnostic Patients with suspected pancreatic cancer will undergo an initial CT scan to determine if a suspect mass is localized and removed by surgery 63% of patients will be diagnosed with non-resectable stage III and IV disease and a biopsy will be undertaken to confirm pancreatic cancer by H&E pathological analysis.  The presence of cancerous cells via pathology is very challenging due to high numbers of non-cancerous stromal infiltrating cells and administration of chemotherapy or enrolment into a clinical trial will only commence on definitive diagnosis of pancreatic cancer. These will notice specifically stains neoplastic pancreatic cells would enable the pathologist to confidently diagnose pancreatic cancer and thus offer appropriate cancer treatment to the patients. The Novel Biomarker BI-010 has been identified as a highly sensitive (98%) and specific (95%) IHC marker for pancreatic cancer and CRT is seeking a partner to develop an IHC based test to detect BI-010 in fine needle aspirate biopsies from biopsy samples.

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. Everyone has a risk of developing cancer, which increases with age. Most individuals who develop cancer do not have a family history. Genetic risk assessment is the evaluation of your personal risk for cancer, based on your family medical history. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

  • Biomarkers in cancer research
  • Biomarkers in medicine
  • Risk assessment, diagnosis
  • Prognosis and treatment predictions
  • Molecular cancer biomarkers

Related Conference of Cancer Biomarkers

June 29-July 01, 2017

International Conference on Hematology and Oncology

Bangkok, Thailand
July 17-19, 2017

19th Euro Congress on Cancer Science and Therapy

Lisbon, Portugal
July 27-28, 2017

4th International Conference and Exhibition on Medical Physics and Biophysics

Rome, Italy - Hotel Holiday Inn Rome
August 28-30, 2017

International Oncologist & Diagnostics Conference

Brussels, Belgium
October 18-20, 2017

25th World Congress on Cancer Science and Therapy

Baltimore, Maryland, USA
October 19-20, 2017

15th World Oncologists Annual Conference

New York ,USA
Oct 19-21, 2017

25th World Cancer Conference

Rome, Italy
October 26-28, 2017

9th International Conference on Biomarkers

Osaka,Japan
November 06-08, 2017

2nd International Congress on Epigenetics & Chromatin

Frankfurt, Germany (H4 Hotel Frankfurt Messe)
November 09-10, 2017

10th World Hematology and Oncology Congress

Vienna, Austria
November 16-17, 2017

World Cancer Meeting

Melbourne, Australia
November 20-22, 2017

14th Asia Pacific
Oncologists Annual Meeting

Melbourne, Australia
November 23-24, 2017

Global Meeting on Molecular & Cancer Biomarkers

Dubai, UAE
November 27-28, 2017

26th World Cancer Convention

Dubai, UAE
November 27- 28, 2017

International Conference on Cancer Diagnostics

Dubai, UAE
December 07-08, 2017

9th World Biomarkers Congress

Madrid, Spain
March 14-16, 2018

Global Summit on Oncology & Cancer

Singapore
May 24-25, 2018

22nd Global Annual Oncologists Meeting

Osaka, Japan

Cancer Biomarkers Conference Speakers

Recommended Sessions

Related Journals

Are you interested in